Posted by Michael Wonder on 12 Sep 2018
Shire granted EU marketing authorization for Veyvondi [vonicog alfa, recombinant von Willebrand factor] for adults with von Willebrand disease
12 September 2018 - Marketing authorisation will enable patient access to Veyvondi throughout Europe.
Shire announced today that the European Commission has granted marketing authorisation for Veyvondi [vonicog alfa, recombinant von Willebrand factor], for the treatment of bleeding events and treatment/prevention of surgical bleeding in adults (age 18 and older) with von Willebrand disease when desmopressin treatment alone is ineffective or not indicated.
Veyvondi is the first and only recombinant von Willebrand Factor treatment in the EU for von Willebrand disease that specifically addresses the primary deficiency or dysfunction of von Willebrand Factor while also allowing the body to restore and maintain adequate Factor VIII plasma levels.
